Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LockBody CD3 bispecific antibody
- Development stage
- Preclinical
- Lead developer
- Centessa Pharmaceuticals
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
LockBody CD3 bispecific antibody is an investigational immuno-oncology agent developed by LockBody Therapeutics, a Centessa Pharmaceuticals company. It utilizes the proprietary LockBody® technology platform, which is designed to create "locked" antibodies that remain inactive in peripheral circulation and selectively "unlock" and activate within the tumor microenvironment. By targeting CD3 to engage T-cells specifically at the tumor site, the therapy aims to maximize anti-tumor effector function while minimizing systemic toxicities, such as cytokine release syndrome, commonly associated with traditional CD3-bispecific T-cell engagers. The program is currently in the preclinical stage of development.
- Other names
- LockBody PlatformLockBody Technology PlatformLockBody antibody technology
02
Targets
CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on LockBody CD3 bispecific antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LockBody CD3 bispecific antibody.